Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling

Hatem A. Azim, Stefan Michiels, Philippe L. Bedard, Sandeep K. Singhal, Carmen Criscitiello, Michail Ignatiadis, Benjamin Haibe-Kains, Martine J. Piccart, Christos Sotiriou, Sherene Loi

Research output: Contribution to journalArticle

Abstract

Purpose: Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biological differences according to age. Experimental Design: Patients were assigned to molecular subtypes [estrogen receptor (ER) +/HER2 -; HER2 +, ER -/HER2 -)] using a three-gene classifier. We evaluated whether previously published proliferation, stroma, and immune-related gene signatures added prognostic information to Adjuvant! online and tested their interaction with age in a Cox model for relapse-free survival (RFS). Furthermore, we evaluated the association between candidate age-related genes or gene sets with age in an adjusted linear regression model. Results: A total of 3,522 patients (20 data sets) were eligible. Patients aged 40 years or less had a higher proportion of ER -/HER2 - tumors (P <0.0001) and were associated with poorer RFS after adjustment for breast cancer subtype, tumor size, nodal status, and histologic grade and stratification for data set and treatment modality (HR=1.34, 95% CI=1.10-1.63, P=0.004). The proliferation gene signatures showed no significant interaction with age in ER +/HER2 - tumors after adjustment for Adjuvant! online. Further analyses suggested that breast cancer in the young is enriched with processes related to immature mammary epithelial cells (luminal progenitors, mammary stem, c-kit, RANKL) and growth factor signaling in two independent cohorts (n = 1,188 and 2,334). Conclusions: Proliferation-related prognostic gene signatures can aid treatment decision-making for young women. However, breast cancer arising at a young age seems to be biologically distinct beyond subtype distribution. Separate therapeutic approaches such as targeting RANKL or mammary stem cells could therefore be needed.

Original languageEnglish
Pages (from-to)1341-1351
Number of pages11
JournalClinical Cancer Research
Volume18
Issue number5
DOIs
Publication statusPublished - Mar 1 2012

Fingerprint

Gene Expression Profiling
Breast Neoplasms
Estrogen Receptors
Genes
Breast
Linear Models
Recurrence
Neoplasms
Survival
Transcriptome
Proportional Hazards Models
Intercellular Signaling Peptides and Proteins
Decision Making
Research Design
Stem Cells
Therapeutics
Epithelial Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. / Azim, Hatem A.; Michiels, Stefan; Bedard, Philippe L.; Singhal, Sandeep K.; Criscitiello, Carmen; Ignatiadis, Michail; Haibe-Kains, Benjamin; Piccart, Martine J.; Sotiriou, Christos; Loi, Sherene.

In: Clinical Cancer Research, Vol. 18, No. 5, 01.03.2012, p. 1341-1351.

Research output: Contribution to journalArticle

Azim, HA, Michiels, S, Bedard, PL, Singhal, SK, Criscitiello, C, Ignatiadis, M, Haibe-Kains, B, Piccart, MJ, Sotiriou, C & Loi, S 2012, 'Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling', Clinical Cancer Research, vol. 18, no. 5, pp. 1341-1351. https://doi.org/10.1158/1078-0432.CCR-11-2599
Azim, Hatem A. ; Michiels, Stefan ; Bedard, Philippe L. ; Singhal, Sandeep K. ; Criscitiello, Carmen ; Ignatiadis, Michail ; Haibe-Kains, Benjamin ; Piccart, Martine J. ; Sotiriou, Christos ; Loi, Sherene. / Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. In: Clinical Cancer Research. 2012 ; Vol. 18, No. 5. pp. 1341-1351.
@article{7941029b357a4bdabcd6ff11e72a293b,
title = "Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling",
abstract = "Purpose: Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biological differences according to age. Experimental Design: Patients were assigned to molecular subtypes [estrogen receptor (ER) +/HER2 -; HER2 +, ER -/HER2 -)] using a three-gene classifier. We evaluated whether previously published proliferation, stroma, and immune-related gene signatures added prognostic information to Adjuvant! online and tested their interaction with age in a Cox model for relapse-free survival (RFS). Furthermore, we evaluated the association between candidate age-related genes or gene sets with age in an adjusted linear regression model. Results: A total of 3,522 patients (20 data sets) were eligible. Patients aged 40 years or less had a higher proportion of ER -/HER2 - tumors (P <0.0001) and were associated with poorer RFS after adjustment for breast cancer subtype, tumor size, nodal status, and histologic grade and stratification for data set and treatment modality (HR=1.34, 95{\%} CI=1.10-1.63, P=0.004). The proliferation gene signatures showed no significant interaction with age in ER +/HER2 - tumors after adjustment for Adjuvant! online. Further analyses suggested that breast cancer in the young is enriched with processes related to immature mammary epithelial cells (luminal progenitors, mammary stem, c-kit, RANKL) and growth factor signaling in two independent cohorts (n = 1,188 and 2,334). Conclusions: Proliferation-related prognostic gene signatures can aid treatment decision-making for young women. However, breast cancer arising at a young age seems to be biologically distinct beyond subtype distribution. Separate therapeutic approaches such as targeting RANKL or mammary stem cells could therefore be needed.",
author = "Azim, {Hatem A.} and Stefan Michiels and Bedard, {Philippe L.} and Singhal, {Sandeep K.} and Carmen Criscitiello and Michail Ignatiadis and Benjamin Haibe-Kains and Piccart, {Martine J.} and Christos Sotiriou and Sherene Loi",
year = "2012",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-11-2599",
language = "English",
volume = "18",
pages = "1341--1351",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling

AU - Azim, Hatem A.

AU - Michiels, Stefan

AU - Bedard, Philippe L.

AU - Singhal, Sandeep K.

AU - Criscitiello, Carmen

AU - Ignatiadis, Michail

AU - Haibe-Kains, Benjamin

AU - Piccart, Martine J.

AU - Sotiriou, Christos

AU - Loi, Sherene

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Purpose: Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biological differences according to age. Experimental Design: Patients were assigned to molecular subtypes [estrogen receptor (ER) +/HER2 -; HER2 +, ER -/HER2 -)] using a three-gene classifier. We evaluated whether previously published proliferation, stroma, and immune-related gene signatures added prognostic information to Adjuvant! online and tested their interaction with age in a Cox model for relapse-free survival (RFS). Furthermore, we evaluated the association between candidate age-related genes or gene sets with age in an adjusted linear regression model. Results: A total of 3,522 patients (20 data sets) were eligible. Patients aged 40 years or less had a higher proportion of ER -/HER2 - tumors (P <0.0001) and were associated with poorer RFS after adjustment for breast cancer subtype, tumor size, nodal status, and histologic grade and stratification for data set and treatment modality (HR=1.34, 95% CI=1.10-1.63, P=0.004). The proliferation gene signatures showed no significant interaction with age in ER +/HER2 - tumors after adjustment for Adjuvant! online. Further analyses suggested that breast cancer in the young is enriched with processes related to immature mammary epithelial cells (luminal progenitors, mammary stem, c-kit, RANKL) and growth factor signaling in two independent cohorts (n = 1,188 and 2,334). Conclusions: Proliferation-related prognostic gene signatures can aid treatment decision-making for young women. However, breast cancer arising at a young age seems to be biologically distinct beyond subtype distribution. Separate therapeutic approaches such as targeting RANKL or mammary stem cells could therefore be needed.

AB - Purpose: Breast cancer in young women is associated with poor prognosis. We aimed to define the role of gene expression signatures in predicting prognosis in young women and to understand biological differences according to age. Experimental Design: Patients were assigned to molecular subtypes [estrogen receptor (ER) +/HER2 -; HER2 +, ER -/HER2 -)] using a three-gene classifier. We evaluated whether previously published proliferation, stroma, and immune-related gene signatures added prognostic information to Adjuvant! online and tested their interaction with age in a Cox model for relapse-free survival (RFS). Furthermore, we evaluated the association between candidate age-related genes or gene sets with age in an adjusted linear regression model. Results: A total of 3,522 patients (20 data sets) were eligible. Patients aged 40 years or less had a higher proportion of ER -/HER2 - tumors (P <0.0001) and were associated with poorer RFS after adjustment for breast cancer subtype, tumor size, nodal status, and histologic grade and stratification for data set and treatment modality (HR=1.34, 95% CI=1.10-1.63, P=0.004). The proliferation gene signatures showed no significant interaction with age in ER +/HER2 - tumors after adjustment for Adjuvant! online. Further analyses suggested that breast cancer in the young is enriched with processes related to immature mammary epithelial cells (luminal progenitors, mammary stem, c-kit, RANKL) and growth factor signaling in two independent cohorts (n = 1,188 and 2,334). Conclusions: Proliferation-related prognostic gene signatures can aid treatment decision-making for young women. However, breast cancer arising at a young age seems to be biologically distinct beyond subtype distribution. Separate therapeutic approaches such as targeting RANKL or mammary stem cells could therefore be needed.

UR - http://www.scopus.com/inward/record.url?scp=84857700943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857700943&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-2599

DO - 10.1158/1078-0432.CCR-11-2599

M3 - Article

C2 - 22261811

AN - SCOPUS:84857700943

VL - 18

SP - 1341

EP - 1351

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -